Possible Common Aetiology behind Maternal Preeclampsia and Congenital Heart Defects in the Child: A Cardiovascular Diseases in Norway Project Study

Paediatric and Perinatal Epidemiology

Volumn 30, Issue 1, 2016, Pages 76-85

  Brodwall, Kristoffer ^a,b   Leirgul, Elisabeth ^a,b   Greve, Gottfried ^a,b   Vollset, Stein Emil ^a,c   Holmstrøm, Henrik ^d   Tell, Grethe S ^a,c   Øyen, Nina ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

congenital heart defects; epidemiology; hypertension; pregnancy

Indexed keywords

ADULT; ARTICLE; ATRIOVENTRICULAR SEPTAL DEFECT; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFANT; MATERNAL AGE; NORWAY; PARITY; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PROGENY; RISK ASSESSMENT; HEART DEFECTS, CONGENITAL; MALE; MOTHER; NEWBORN; ODDS RATIO; PATHOPHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PREVALENCE; REGISTER; RISK FACTOR;

ADULT; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; MALE; MOTHERS; NORWAY; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANT WOMEN; PREVALENCE; REGISTRIES; RISK FACTORS;

EID: 84958832297     PISSN: 02695022     EISSN: 13653016     Source Type: Journal    
DOI: 10.1111/ppe.12252     Document Type: Article

References (35)

1. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, et al. Noninherited risk factors and congenital cardiovascular defects: Current knowledge: A scientific statement from the American Heart Association council on cardiovascular disease in the young: Endorsed by the American Academy of Pediatrics. Circulation 2007; 115: 2995-3014.
2. Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, et al. Association between maternal chronic conditions and congenital heart defects: A population-based cohort study. Circulation 2013; 128: 583-589.
3. Vesce F, Farina A, Giorgetti M, Jorizzo G, Bianciotto A, Calabrese O, et al. Increased incidence of preeclampsia in pregnancies complicated by fetal malformation. Gynecologic and Obstetric Investigation 1997; 44: 107-111.
4. Conde-Agudelo A, Belizán JM,. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. British Journal of Obstetrics and Gynecology 2000; 107: 75-83.
5. Nelson DB, Chalak LF, McIntire DD, Leveno KJ,. Is preeclampsia associated with fetal malformation? A review and report of original research. The Journal of Maternal-Fetal & Neonatal Medicine 2014; 14: 1-6.
6. Cedergren MI, Källén BAJ,. Obstetric outcome of 6346 pregnancies with infants affected by congenital heart defects. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2006; 125: 211-216.
7. Ness RB, Roberts JM,. Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. American Journal of Obstetrics and Gynecology 1996; 175: 1365-1370.
8. Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratinam S,. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: A meta-analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2014; 182: 194-201.
9. Hagemo PS,. BERTE - a database for children with congenital heart defects. Studies in Health Technology and Informatics 1994; 14: 98-101.
10. Sulo G, Igland J, Vollset SE, Nygård O, Øyen N, Tell GS,. Cardiovascular disease and diabetes mellitus in Norway during 1994-2009 CVDNOR - a nationwide research project. Norsk Epidemiologi 2013; 23: 101-107.
11. Leirgul E, Fomina T, Brodwall K, Greve G, Holmstrøm H, Vollset SE, et al. Birth prevalence of congenital heart defects in Norway 1994-2009-A nationwide study. American Heart Journal 2014; 168: 956-964.
12. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A,. Seeking causes: Classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Research. Part A, Clinical and Molecular Teratology 2007; 79: 714-727.
13. Klungsøyr K, Harmon QE, Skard LB, Simonsen I, Austvoll ET, Alsaker ER, et al. Validity of pre-eclampsia registration in the medical birth registry of Norway for women participating in the Norwegian Mother and Child Cohort Study, 1999-2010. Paediatric and Perinatal Epidemiology 2014; 28: 362-371.
14. Roberts JM, Hubel CA,. The two stage model of preeclampsia: Variations on the theme. Placenta 2009; 30 (Suppl.): 32-37.
15. Zhong Y, Tuuli M, Odibo AO,. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenatal Diagnosis 2010; 30: 293-308.
16. Govender L, Mackraj I, Gathiram P, Moodley J,. The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: Early- versus late-onset pre-eclampsia. Cardiovascular journal of Africa 2012; 23: 153-159.
17. Sliwa K, Mebazaa A,. Possible joint pathways of early pre-eclampsia and congenital heart defects via angiogenic imbalance and potential evidence for cardio-placental syndrome. European Heart Journal 2014; 35: 680-682.
18. Llurba E, Sánchez O, Ferrer Q, Nicolaides KH, Ruíz A, Domínguez C, et al. Maternal and foetal angiogenic imbalance in congenital heart defects. European Heart Journal 2014; 35: 701-707.
19. Steinberg G, Khankin EV, Karumanchi SA,. Angiogenic factors and preeclampsia. Thrombosis Research 2009; 123: S93-S99.
20. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters and angiogenic factors. Prenatal Diagnosis 2014; 34: 1-9.
21. Pinheiro CC, Rayol P, Gozzani L, Reis LM, dos Zampieri G, Dias CB, et al. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenatal Diagnosis 2014; 34: 1-9.
22. Myatt L, Clifton R, Roberts J, Spong C, Wapner R, Thorp J Jr, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous. British Journal of Obstetrics and Gynecology 2013; 120: 1183-1191.
23. Kleinrouweler C, Wiegerinck M, Ris-Stalpers C, Bossuyt P, van der Post J, von Dadelszen P, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: A systematic review and meta-analysis. British Journal of Obstetrics and Gynecology 2012; 119: 778-787.
24. Myers JE, Kenny LC, McCowan LME, Chan EHY, Dekker GA, Poston L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: A predictive test accuracy study. British Journal of Obstetrics and Gynecology 2013; 120: 1215-1223.
25. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S,. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. Journal of Reproductive Immunology 2009; 82: 106-111.
26. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. The New England Journal of Medicine 2004; 350: 672-683.
27. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ,. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-487.
28. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. The Journal of Maternal-Fetal & Neonatal Medicine 2008; 21: 9-23.
29. Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen A-K, Taipale P, et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy and Childbirth 2013; 13: 110.
30. Tsao P-N, Wei S-C, Su Y-N, Chou H-C, Chen C-Y, Hsieh W-S,. Excess soluble fms-like tyrosine kinase 1 and low platelet counts in premature neonates of preeclamptic mothers. Pediatrics 2005; 116: 468-472.
31. Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, et al. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development (Cambridge, England) 2001; 128: 1531-1538.
32. Smedts HPM, Isaacs A, De Costa D, Uitterlinden AG, van Duijn CM, Gittenberger-de Groot AC, et al. VEFG polymorphisms are associated with endocardial cushion defects: A family-based case-control study. Pediatric Research 2010; 67: 23-28.
33. Ackerman C, Locke AE, Feingold E, Reshey B, Espana K, Thusberg J, et al. An excess of deleterious variants in VEGF-A pathway genes in down-syndrome-associated atrioventricular septal defects. American Journal of Human Genetics 2012; 91: 646-659.
34. Skjærven R, Melve KK,. Selective fertility-the examples of perinatal death and preeclampsia. Norsk Epidemiologi 2007; 17: 175-180.
35. Stothard KJ, Tennant PWG, Bell R, Rankin J,. Maternal overweight and obesity and the risk of congenital anomalies. The Journal of the American Medical Association 2009; 301: 636-650.